Cantor Fitzgerald Reiterates Neutral on Fate Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated a Neutral rating on Fate Therapeutics (NASDAQ:FATE) and maintained a $5 price target.
September 07, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating on Fate Therapeutics and maintained a $5 price target.
The news is directly about Fate Therapeutics and its rating by Cantor Fitzgerald. The Neutral rating suggests that the analyst does not expect significant price movement in the short term. The maintained price target indicates that the analyst's valuation of the company has not changed.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100